|Bid||2.8300 x 3200|
|Ask||2.8400 x 900|
|Day's Range||2.0800 - 2.5900|
|52 Week Range||1.9100 - 45.4400|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.70|
Tonix Pharmaceuticals (NASDAQ: TNXP) is a biotech stock that's having an absolutely awful week. On Wednesday, the company's shares fell sharply for a third straight day, closing more than 13% lower. Investors are clearly shaken by Tonix's current attempt at financial engineering.
Tonix Exercises Option to License Antiviral Technology PlatformNEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and o
Shares of Tonix Pharmaceuticals Holding (NASDAQ: TNXP) were crashing 22.7% as of 10:54 a.m. ET on Tuesday. This stock split took effect today. Reverse stock splits aren't a sign that things are going well for a company.